Table 1 Baseline characteristics of the patients (N = 439)
Female, n (%) | 296 (67.4%) |
Age (yrs.), mean (SD) | 59.8 (10.8) |
Disease duration (yrs.), median (IQR) | 10 (6–17) |
BMI, mean (SD) | 25.9 (4.3) |
Normal BMI (18.5–25), n (%) | 174 (39.6%) |
RF positive, n (%) | 270 (67.3%) |
ACPA positive, n (%) | 277 (69.1%) |
Erosive disease, n (%) | 252 (62.8%) |
ESR, median (IQR) | 9.0 (5–17) |
TJC28, median (IQR) | 0 (0–1) |
SJC28, median (IQR) | 0 (0–0) |
PGA, median (IQR) | 20.7 (9.0–28.1) |
DAS28-ESR, mean (SD) | 2.0 (0.8) |
MBDA score, mean (SD) | 30.2 (12.6) |
Low (< 30) or moderate (30–44), n (%) | 375 (85.4%) |
Type of TNFi, n (%) | |
Etanercept | 176 (40.1%) |
Adalimumab | 225 (51.3%) |
Infliximab | 22 (5.0%) |
Golimumab | 14 (3.2%) |
Certolizumab | 2 (0.5%) |
Number of TNFi, n (%) | |
1st | 379 (86.5%) |
2nd | 50 (11.4%) |
3rd | 9 (2.1%) |
csDMARD, n (%) | |
Methotrexate | 362 (82.5%) |
Methotrexate + glucocorticoids | 20 (4.6%) |
Glucocorticoids | 6 (1.4%) |
Other csDMARD | 29 (6.6%) |
No DMARD | 22 (5.0%) |